

1030839

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



09038298

TEMPORARY
FORM D
NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

SEC
Mail Processing
Section

MAR 16 2009

Washington, DC
121

OMB APPROVAL	
OMB Number:	3235-0076
Expires:	March 15, 2009
Estimated average burden hours per form.....	4.00

SEC USE ONLY		
Prefix		Serial
DATE RECEIVED		

Name of Offering (check if this is an amendment and name has changed, and indicate change.)

Offering of Convertible Promissory Notes

Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4(6) ULOE

Type of Filing: New Filing Amendment

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer (check if this is an amendment and name has changed, and indicate change.)

Synovics Pharmaceuticals, Inc.

Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
5360 Northwest 35 th Avenue, Ft. Lauderdale, FL 33309	954-486-4590

Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices)	Telephone Number (Including Area Code)

Brief Description of Business

Pharmaceutical products

Type of Business Organization

corporation limited partnership, already formed other (please specify):
 business trust limited partnership, to be formed

Month Year

Actual or Estimated Date of Incorporation or Organization*: [1][0] [9][0] Actual Estimated

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction) [N][V]

GENERAL INSTRUCTIONS Note: This is a special Temporary Form D (17 CFR 239.500T) that is available to be filed instead of Form D (17 CFR 239.500) only to issuers that file with the Commission a notice on Temporary Form D (17 CFR 239.500T) or an amendment to such a notice in paper format on or after September 15, 2008 but before March 16, 2009. During that period, an issuer also may file in paper format an initial notice using Form D (17 CFR 239.500) but, if it does, the issuer must file amendments using Form D (17 CFR 239.500) and otherwise comply with all the requirements of § 230.503T.

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W. Washington, D.C. 20549.

Copies Required: Two (2) copies of this notice must be filed with the SEC, one of which must be manually signed. The copy not manually signed must be photocopy of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION:

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Gange, Jyotindra

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Synovics Pharmaceuticals, Inc., 5360 Northwest 35th Avenue, Ft. Lauderdale, FL 33309

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Lane, Ronald H.

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Synovics Pharmaceuticals, Inc., 5360 Northwest 35th Avenue, Ft. Lauderdale, FL 33309

Check Box(es) that Apply: Promoter Beneficial Owner Executive Owner Director General Partner

Full Name (Last name first, if individual)

Sapte, Vinay

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Synovics Pharmaceuticals, Inc., 5360 Northwest 35th Avenue, Ft. Lauderdale, FL 33309

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Sapte, Maneesh

Business or Residence Address (Number and Street, City, State, Zip Code)

23, Kalpataru Court, Dr. C. G. Road, Chembur, Mumbai, Maharashtra 400 074

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Maneesh Pharmaceuticals Ltd.

Business or Residence Address (Number and Street, City, State, Zip Code)

23, Kalpataru Court, Dr. C. G. Road, Chembur, Mumbai, Maharashtra 400 074

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Singh, Harcharan

Business or Residence Address (Number and Street, City, State, Zip Code)

10 Waterloo Court, Thornhill, Ontario L3T 6L9

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Lionhart Investments, Ltd.*

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Photon Global Ltd., Heston Business Court, 19 Camp Road, Wimbledon, UK

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

2133820 Ontario Inc.

Business or Residence Address (Number and Street, City, State, Zip Code)

265 Rimrock Road, Suite 1, North York, Ontario, M3J 3C6, Canada

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Singh, Prembala

Business or Residence Address (Number and Street, City, State, Zip Code)

265 Rimrock Road, Suite 1, North York, Ontario, M3J 3C6, Canada

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Svizera Holdings BV

Business or Residence Address (Number and Street, City, State, Zip Code)

Antennestraat 43, Post Box 60300, Almere P7 1320 AY

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General Partner

Full Name (Last name first, if individual)

Desai, Mahendra

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Synovics Pharmaceuticals, Inc., 5360 Northwest 35th Avenue, Ft. Lauderdale, FL 33309

* The beneficial ownership of common stock of the Issuer held by the referenced person is subject to a beneficial ownership limitation not exceeding 9.99%.

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero". If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

Type of Security	Aggregate Offering Price	Amount Already Sold
Debt.....	\$0	\$0
Equity.....	\$0	\$0
Common Preferred		
Convertible Securities (including warrants).....	\$0	\$0
Partnership Interests.....	\$0	\$0
Other: Series C Preferred Stock and Common Stock Warrants	\$25,000,000	\$13,382,292(1)
Total.....	<u>\$25,000,000</u>	<u>\$13,382,292(1)</u>

Answer also in Appendix, Column 3, if filing under ULOE.

(1) Includes convertible bridge notes in the principal amount of \$5,202,292 which "rolled" over into the offering being reported herein.

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."

	Number Investors	Aggregate Dollar Amount Of Purchase
Accredited Investors.....	<u>7</u>	<u>\$13,382,292</u>
Non-accredited Investors	<u>0</u>	<u>\$0</u>
Total (for filings under Rule 504 only).....	<u>0</u>	<u>\$0</u>

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.

Type of offering	Type of Security	Dollar Amount Sold
Rule 505	_____	\$ _____
Regulation A	_____	\$ _____
Rule 504	_____	\$ _____
Total.....	_____	\$ _____

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

Transfer Agent's Fees.....		\$0
Printing and Engraving Costs.....		\$0
Legal Fees	<input checked="" type="checkbox"/>	\$50,000
Accounting Fees.....		\$0
Engineering Fees.....		\$0
Sales Commissions (specify finders' fees separately)	<input checked="" type="checkbox"/>	\$470,874(1)
Other Expenses... Filing fees and placement agent expenses.....	<input checked="" type="checkbox"/>	\$35,509
Total.....	<input checked="" type="checkbox"/>	<u>\$556,383</u>

(1) Includes commission payable for notes sold which were convertible into the Issuer's Series C preferred stock reported herein.

\$24,443,617

Enter the differences between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Questions 4.b above.

	Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees.....	\$ 0		\$ 0
Purchase of real estate.....	\$ 0		\$ 0
Purchase, rental or leasing and installation of machinery and equipment.....	\$ 0		\$ 0
Construction or leasing of plant buildings and facilities.....	\$ 0		\$ 0
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger).....	\$ 0		\$ 0
Repayment of indebtedness.....	\$ 0	<input checked="" type="checkbox"/>	
Working capital.....	\$ 0	<input checked="" type="checkbox"/>	\$9,549,004(1)
Other (specify):	\$ 0	<input checked="" type="checkbox"/>	\$14,894,613(1)(2)
Column Totals.....	\$ 0	<input checked="" type="checkbox"/>	\$24,443,617
Total Payments Listed (column totals added).....	<input checked="" type="checkbox"/> \$24,443,617		

(1) Includes use of adjusted gross proceeds from "roll over" of convertible notes referenced above.

(2) A portion of the adjusted gross proceeds may have been used to pay compensation due to the officers, directors and affiliates of the issuer in the regular course of business.

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type)	Signature	Date
Synovics Pharmaceuticals, Inc.		March 12, 2009
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
Mahendra Desai	Chief Financial Officer	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)